Plain-English translation of NCT07487480 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following people with Crohn's disease whose symptoms didn't improve with a previous medication called ustekinumab. Researchers want to understand how well a new medication called guselkumab works for these patients and whether it is safe. This new treatment targets a different part of the immune system that causes inflammation in Crohn's disease.
Many people with Crohn's disease don't respond well to available treatments, or they stop working over time. Doctors need real-world information about whether this medication can help patients who haven't benefited from other biologic therapies, so they can make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning researchers will follow your progress over time rather than randomly assigning you to different treatment groups. You will receive the new medication as part of your regular care and will attend study visits to share information about how you're doing, report any side effects, and complete disease activity assessments. The study involves tracking your health over time to gather real-world evidence about how well this treatment works for people in your situation.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China